8-K: Interpace Biosciences Restructures Preferred Stock in Bid for Nasdaq Uplisting

Interpace Biosciences has exchanged its Series B preferred stock for a new Series C preferred stock, a move aimed at facilitating a potential uplisting to the Nasdaq stock exchange.

Summary

• Interpace Biosciences has entered into an exchange agreement with its Series B preferred stock investors, Ampersand Capital Partners and 1315 Capital.
• The investors exchanged 47,000 shares of Series B preferred stock for 47,000 newly created shares of Series C preferred stock.
• The Series C preferred stock has a conversion price of $2.02 per share, matching the closing price of the common stock on the date of the agreement.
• The Series C preferred stock does not include certain rights that were attached to the Series B preferred stock, such as liquidation preferences and director designation rights.
• The Series C preferred stock will automatically convert into common stock upon a Nasdaq uplisting.
• The company believes the new Series C preferred stock will be classified as stockholders equity under generally accepted accounting principles.
• This exchange is considered a first step towards a potential Nasdaq uplisting, which the company believes will help raise capital and increase investor interest.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a strategic move to improve the company's capital structure and pursue a Nasdaq uplisting. While there are risks associated with the uplisting, the overall tone is optimistic about the company's future prospects.

Positives

• The restructuring simplifies the capital structure by removing certain restrictive rights associated with the Series B preferred stock.
• The automatic conversion of Series C preferred stock upon a Nasdaq uplisting aligns investor interests with the company's goal of uplisting.
• The company believes the new Series C preferred stock will be classified as stockholders equity, which could improve the company's balance sheet.
• The potential Nasdaq uplisting could increase investor interest and trading volume in the company's common stock.

Negatives

• The Series C preferred stock holders have given up certain protective rights, such as liquidation preferences and director designation rights.
• The company still needs to meet Nasdaq's stockholder equity and minimum bid price requirements for a successful uplisting.

Risks

• The company may not be able to meet all the requirements for a Nasdaq uplisting.
• There is no guarantee that the uplisting will result in increased investor interest or trading volume.
• The company may need to take additional steps to satisfy Nasdaq listing requirements, which could be costly or time-consuming.

Future Outlook

The company intends to pursue a Nasdaq uplisting, which it believes will assist in raising additional capital, increasing investor interest and trading volume, and pursuing acquisitions. The company may need to take additional steps to satisfy Nasdaq listing requirements.

Management Comments

• Tom Burnell, Chairman, President and CEO of Interpace said, 'The Company has considered a number of opportunities over the past several years to adjust its capital structure that would allow for raising growth capital given the Companys recent strong financial performance.'
• Burnell added, 'The willingness of Ampersand Capital Partners and 1315 Capital to partner with the Company for the long-term benefit of all shareholders, and, most importantly, the patients we serve, is truly appreciated.'
• Burnell also stated, 'The agreed-to exchange between the Company and its Preferred Shareholders will undoubtedly create further opportunities to extend this mission.'

Industry Context

The move to restructure the preferred stock and seek a Nasdaq uplisting is likely driven by a desire to improve the company's access to capital markets and enhance its visibility within the investment community. This is a common strategy for companies looking to grow and expand their operations.

Comparison to Industry Standards

• The restructuring of preferred stock to facilitate a Nasdaq uplisting is a common practice among companies seeking to improve their access to capital markets.
• Many biotech and diagnostics companies have pursued similar strategies to enhance their visibility and attract institutional investors.
• Companies like Exact Sciences and Guardant Health have successfully uplisted to major exchanges, which has often led to increased trading volume and market capitalization.
• The specific terms of the Series C preferred stock, such as the conversion price and the removal of certain protective rights, are tailored to Interpace's specific situation and are not directly comparable to other companies.
• The success of the uplisting will depend on Interpace's ability to meet Nasdaq's listing requirements, which include minimum share price and shareholder equity thresholds.

Related Party Transactions

• The exchange of Series B preferred stock for Series C preferred stock is a related party transaction involving Ampersand Capital Partners and 1315 Capital.

Stakeholder Impact

• Shareholders may benefit from a potential Nasdaq uplisting, which could increase the value of their shares.
• Employees may benefit from the company's improved financial position and growth prospects.
• Customers may benefit from the company's continued investment in molecular diagnostics and personalized medicine.
• Creditors may benefit from the company's improved financial stability and access to capital.

Next Steps

• The company will seek an uplisting of its common stock to Nasdaq.
• The company may need to take additional steps to satisfy Nasdaq listing requirements.
• The company will continue to operate its business and provide molecular diagnostic tests and services.

Key Dates

Keywords

Interpace Biosciences, preferred stock, Series C, Series B, Nasdaq, uplisting, capital structure, conversion, equity, investors, Ampersand Capital Partners, 1315 Capital